A first-in-human phase I study to evaluate the fully human monoclonal antibody MNRP1685A (anti-NRP1) administered intravenously every three weeks in patients with advanced solid tumors.
Year: 2010
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: C. D. Weekes, P. Hegde, Y. Xin, R. Yu, H. Xiang, M. Beeram, L. Gore, R. K. Brachmann, A. Patnaik
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2231017067